ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a liquid biopsy company, announced that it achieved a significant milestone in 2022, with clearance from the US Food & Drug Administration (FDA) and
Angle PLC Pharma Services Contract with Crescendo Biologics
ANGLE PLC (AIM: AGL, OTCQX: ANPCY) has signed an agreement with Crescendo Biologics, a clinical-stage immuno-oncology company, to offer its advanced Portrait Flex Assay, a liquid biopsy tool, for a
Oracle Power PLC (AIM:ORCP) MoU with U.S. Hydrogen Fuel Cell Company
MoU with U.S. hydrogen fuel cell company to explore heavy-duty transport & port infrastructure development
Genflow Biosciences (LON:GENF) Research Agreement Signed with Magnitude Biosciences Limited
Genflow (LSE: GENF) is pleased to announce it has entered into a research agreement with Magnitude Biosciences Limited (“Magnitude”), a UK-based, specialist biotechnology research organisation that supports drug discovery and
Angle PLC (AIM:AGL) Spread of breast cancer accelerates during sleep
CTCs, CTC clusters and CTC-WBC clusters harvested using Parsortix were more numerous and more aggressive in initiating metastasis during sleep
Angle PLC (AIM:AGL) Molecular characterisation of CTCs
PARSORTIX ENABLES MOLECULAR CHARACTERISATION OF CTCS ISOLATED FROM FROZEN SAMPLES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND SARCOMA
Genflow Biosciences (LON:GENF) International patent application
Patent portfolio strengthened with international patent application under the Patent Cooperation Treaty
Genflow Biosciences Plc (LSE:GENF) Company Update
Genflow (LSE: GENF), a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of ageing and diseases associated with advanced age, is pleased to
AFC Energy Plc (AFC.L) Extreme E 2022 Season Contract
AFC Energy (AIM: AFC), a leading provider of hydrogen power generation technologies, is pleased to announce that Extreme E, the all-electric SUV racing series , will continue to use the
Genflow Biosciences (GENF.L) First Day of Dealings
Admission to the Official List
Green light for small cell lung cancer treatment given to AstraZeneca in China
Based on positive results in a phase III trial, Imfinzi demonstrated improvement over chemotherapy alone, the approval was granted
Braveheart Inv Group (BRH.L) Further re Paraytec Limited
Braveheart is pleased to provide an update concerning the development of a COVID-19 test that Paraytec Limited is conducting with the University of Sheffield.